{
    "nctId": "NCT05050890",
    "briefTitle": "Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia",
    "officialTitle": "Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasm",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 38,
    "primaryOutcomeMeasure": "The concentration of circulating DNA(ctDNA)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Information to the patient and signed informed consent;\n* Locally advanced breast cancer that is a candidate for neoadjuvant therapy;\n* Histological diagnosis of localized invasive breast carcinoma, confirmed by the pathologist, with or without expression of hormone receptors, and/or with the presence of HER-2.\n\nExclusion Criteria:\n\n* Metastatic breast cancer (Stage IV);\n* Additional invasive malignant disease;\n* Known psychiatric or substance abuse disorders that may interfere with cooperation with study requirements;\n* Presents any organic condition that makes it impossible to carry out chemotherapy treatment;\n* Pregnant or lactating women\n* Received previous treatment for breast cancer.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}